Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
641-653 of 653 trials

Chikungunya Vaccine: Effectiveness and Safety Study

We are evaluating how well the chikungunya vaccine works in preventing severe disease and hospitalizations in at-risk populations. This study aims to understand the vaccine's real-life impact on health outcomes.

Chikungunya1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Parkinson's Disease: New Investigational Compound

We are investigating a new treatment for Parkinson's disease in both healthy individuals and patients. The goal is to assess its safety and effectiveness in managing neurological symptoms.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

IgA Nephropathy: Atacicept Treatment Study

We are testing a new medication, atacicept, to see if it helps patients with IgA nephropathy by reducing a specific protein in the blood. We will also monitor its safety and how it affects other immune factors.

IgA Nephropathy (Berger's Disease)1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNephrology

New Treatment for Patients with XXX Cancer

We are exploring a new combination therapy for people with XXX cancer who need a second-line treatment. The goal is to see if this approach is safer and more effective than standard care.

Cancer Eligible for Second-Line Treatment1-2 yearsSafety phase (I)Oncology

EGL-003 for Autoimmune Diseases

We are testing a new treatment called EGL-003 to see how safe it is and how the body handles it. The study starts with healthy volunteers and then includes adults with autoimmune diseases.

Atopic Dermatitis1-2 yearsSafety phase (I)DermatologyRheumatology

Hereditary Angioedema: Navenibart Treatment Study

We are studying whether navenibart can help prevent attacks in adults and adolescents with hereditary angioedema. The trial will also look at its safety and how it affects quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Rheumatoid Arthritis: Tulisokibart Study

We are testing a new medication called tulisokibart for people with rheumatoid arthritis to see if it helps reduce symptoms better than a placebo. The study will also assess the safety and tolerability of this treatment.

Rheumatoid Arthritis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

RSV Immunization Study: Nirsevimab for Infants

We are studying how the nirsevimab immunization affects infants' immune responses to RSV infections. This research aims to understand the role of age, weight, and maternal antibodies in developing immunity.

Healthy Infants1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Familial Polycythemia: New Drug Treatment Study

We are testing a new drug for individuals with familial polycythemia caused by an EPO gene mutation. The goal is to see if it is safe and effective in managing their condition.

Familial Polycythemia with EPO Gene Mutation1-2 yearsSafety phase (I)Hematology

Cold-Induced Urticaria: GTX-B001 Treatment

We are testing a new treatment for people with cold-induced urticaria to see how well it is tolerated and its effects on symptoms. The study includes both healthy volunteers and patients.

Cold-Induced Urticaria1-2 yearsSafety phase (I)AllergologyDermatology

NTX-1955: CO2 Challenge Study

We are testing a new treatment called NTX-1955 in healthy participants to see how it affects carbon dioxide levels in the body. This research may help us understand its potential uses in health.

Generalized Anxiety Disorder1-2 yearsSafety phase (I)Psychiatry

Chronic Constipation: Lecicarbon® Treatment Study

We are evaluating the safety and tolerability of long-term treatment with Lecicarbon® for people with chronic constipation. This study aims to understand how well patients can manage this treatment over time.

Chronic Constipation1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterology

CTNNB1 Syndrome: Gene Therapy Study for Kids

We are testing a new gene therapy given through an injection in the brain for children with CTNNB1 syndrome. The study aims to see if it is safe and if it may help improve their condition.

CTNNB1 Syndrome1-2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics